三阴性乳腺癌 (TNBC) 被定义为激素受体和人表皮生长因子受体 2 表达稀缺，被认为是乳腺癌中异质性最强的亚型，预后最差。尽管精确分型和定制治疗方法取得了快速进展，但随之而来的癌症治疗相关心血管毒性 (CTR-CVT) 可能会对 TNBC 幸存者产生不利影响。如今，这一跨学科问题越来越受到心脏病学家、肿瘤学家和其他相关专家的关注，推动心脏肿瘤学成为一个蓬勃发展的领域，重点关注具有潜在心血管威胁的癌症患者的全程管理。在这篇综述中，我们首先概述了 TNBC 不断发展的分子亚型和治疗前景。此外，我们还介绍了 CTR-CVT 的各种监控方法。在正文中，我们详细阐述了抗TNBC治疗带来的典型心脏毒性，从化疗（特别是蒽环类药物）、手术、麻醉、放疗到免疫治疗，并展望了人工智能和中医时代的未来发展方向.版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

Defined as scarce expression of hormone receptors and human epidermal growth factor receptor 2, triple-negative breast cancer (TNBC) is labeled as the most heterogeneous subtype of breast cancer with poorest prognosis. Despite rapid advancements in precise subtyping and tailored therapeutics, the ensuing cancer therapy-related cardiovascular toxicity (CTR-CVT) could exert detrimental impacts to TNBC survivors. Nowadays, this interdisciplinary issue is incrementally concerned by cardiologists, oncologists and other pertinent experts, propelling cardio-oncology as a booming field focusing on the whole-course management of cancer patients with potential cardiovascular threats. Here in this review, we initially profile the evolving molecular subtyping and therapeutic landscape of TNBC. Further, we introduce various monitoring approaches of CTR-CVT. In the main body, we elaborate on typical cardiotoxicities ensuing anti-TNBC treatments in detail, ranging from chemotherapy (especially anthracyclines), surgery, anesthetics, radiotherapy to immunotherapy, with future perspectives on promising directions in the era of artificial intelligence and traditional Chinese medicine.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.